Finance

Beta
Lists
ASND:NASDAQ
Ascendis Pharma A/S
$210.45
-3.83%
(-8.39) 1D
$210.45
0.00% (0.00)
After hours
Closed: Jun 5, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ASND...
Open
$220.51
High
$222.55
Low
$209.56
Mkt. cap
13.07B
Avg. vol.
692.21K
Volume
556.36K
P/E ratio
23.87
52-wk high
$250.74
52-wk low
$161.09
EPS
$8.82
Shares outstanding
62.38M
No. of employees
1K
Open
$220.51
High
$222.55
Low
$209.56
Mkt. cap
13.07B
Avg. vol.
692.21K
Volume
556.36K
P/E ratio
23.87
52-wk high
$250.74
52-wk low
$161.09
EPS
$8.82
Shares outstanding
62.38M
No. of employees
1K
Analyst outlook
Analyst Ratings
Based on 15 analysts giving stock ratings to ASND in the past 3 months
Strong Buy
Buy
15
Hold
0
Sell
0
12 month forecast
Based on 15 Wall Street analysts offering 12 month price targets for ASND in the last 3 months.
Highest
Current $210.45
$355.00 (+68.69%)
Average
$303.00 (+43.98%)
Lowest
$255.00 (+21.17%)
News stories
From sources across the web
About Ascendis Pharma A/S
CEOJan Møller Mikkelsen
Employees1.19K
Founded2006
Headquarters-
SectorBiotechnology
Last report
May 7, 2026
Fiscal period
Q1 2026
EPS / Est. (EUR)
€0.27 / €0.14
+90.14%beat
Revenue / Est. (EUR)
246.60M / 267.66M
-7.87%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in EUR
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
158.04M
213.63M
247.50M
246.60M
Cost of goods sold
31.45M
22.35M
23.60M
17.52M
Cost of revenue
31.45M
22.35M
23.60M
17.52M
Research and development expenses
71.99M
66.88M
82.20M
59.04M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
107.56M
113.40M
139.31M
145.23M
Operating expense
179.55M
180.28M
221.51M
204.27M
Total operating expenses
211.00M
202.64M
245.11M
221.79M
Operating income
-52.95M
11.00M
2.39M
24.81M
Other non operating income
-
-
-105.57M
-
EBT including unusual items
-35.01M
-57.37M
-26.70M
-48.18M
EBT excluding unusual items
-35.01M
-57.37M
-34.21M
-48.18M
Income tax expense
3.85M
3.62M
6.86M
-677.52M
Effective tax rate
-10.99%
-6.30%
-25.68%
1,406.31%
Other operating expenses
-
-
-
-
Net income
-38.86M
-60.99M
-33.56M
629.34M
Net profit margin
-24.58%
-28.55%
-13.56%
255.21%
Earnings per share
-0.64
-1.00
-0.55
0.27
Interest and investment income
55.06M
6.04M
64.06M
4.52M
Interest expense
-33.02M
-66.90M
-74.65M
-67.26M
Net interest expenses
22.04M
-60.87M
-10.59M
-62.74M
Depreciation and amortization charges
-
-
-
-
EBITDA
-48.64M
15.02M
3.60M
29.03M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more

Research

AI content may include mistakes. Learn more